US clears updated COVID boosters targeting newest variants U.S. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain The Independent UK · Aug 31, 2022
FDA greenlights new COVID-19 booster despite limited data - Roll Call The Food and Drug Administration granted emergency authorization to Pfizer and Moderna for updated COVID-19 booster shots. Roll Call · Aug 31, 2022
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular… Benzinga · Aug 30, 2022
This Is What Whales Are Betting On Moderna Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Aug 30, 2022
Moderna's COVID vaccine lawsuit looks ahead to future markets Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets Axios · Aug 29, 2022
Omicron COVID-19 booster shots are coming: What you need to know The next generation of COVID-19 booster shots — tailored specifically to combat the highly infectious family of omicron subvariants — could roll out early next month. Los Angeles Times · Aug 28, 2022
Q&A: The new COVID vaccine booster is coming. Should you get it? The COVID-19 vaccine is getting an upgrade. Tribune News Service · Aug 28, 2022
What Are Whales Doing With Moderna Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Aug 26, 2022
Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%… Asharq Al-Awsat · Aug 26, 2022
US Covid vaccine maker Moderna suing rivals Pfizer and BioNTech over jab The company said it believes its rivals’ vaccine infringes on patents Moderna filed between 2010 and 2016 Wales Online · Aug 26, 2022
Pfizer asks EU drug regulator to OK tweaked COVID vaccine Pharmaceuticals Pfizer and BioNTech say they have asked the European Medicines Agency to authorize their updated coronavirus booster vaccine that includes the most recent omicron subvariants The Independent UK · Aug 26, 2022
Moderna sues Pfizer over COVID-19 vaccine patents The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines. WEKU · Aug 26, 2022
Moderna sues Pfizer and BioNTech over Covid-19 vaccine The vaccine maker said it had filed patent infringement lawsuits in the US and Germany. The Independent UK · Aug 26, 2022
Moderna sues Pfizer/BioNTech alleging patent infringement over Covid vaccine Moderna seeks unspecified damages in lawsuit over rivals’ jab Evening Standard · Aug 26, 2022
Evening Standard · Aug 26, 2022 Covid infections at lowest level in two months- ONS High levels of coronavirus antibodies among the population means the rate of serious illness remains low
Tribune News Service · Aug 26, 2022 Moderna sues Pfizer, BioNTech over COVID vaccine technology Moderna Inc. sued Pfizer Inc. and BioNTech SE, claiming the technology in their COVID-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the vaccine titans.
Bangkok Post · Aug 26, 2022 Moderna sues Pfizer over Covid vaccine Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first Covid-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.
The Independent UK · Aug 26, 2022 Moderna sues Pfizer over patents behind COVID-19 vaccine COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech, accusing the rivals of copying Moderna’s technology in order to make their own vaccine
The Independent UK · Aug 26, 2022 Moderna sues Pfizer-BioNTech accusing them of copying Covid shot technology ‘We believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permission,’ Moderna legal officer says
Axios · Aug 26, 2022 Moderna sues Pfizer, BioNTech over COVID-19 vaccine The lawsuit seeks unspecified monetary damages for patent infringement.
The Independent UK · Aug 25, 2022 Tweaked COVID boosters close but how much will they help? COVID-19 vaccines tweaked to better match today’s omicron threat are expected to roll out in a few weeks but how much will they help
Benzinga · Aug 23, 2022 Moderna Whale Trades For August 23 A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 53 strange trades.
Tribune News Service · Aug 22, 2022 Pfizer files application for booster against latest variants Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.
Wales Online · Aug 18, 2022 Everything you need to know about the new Covid vaccine that targets omicron variant o serious safety concerns have been identified for this new bivalent treatment
Daily Mirror · Aug 16, 2022 All over-50s to get a new Covid jab targeted to protect against Omicron variant Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine